NAYA Biosciences, Inc (NAYA) - Total Assets
Based on the latest financial reports, NAYA Biosciences, Inc (NAYA) holds total assets worth $46.45 Million USD as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NAYA Biosciences, Inc - Total Assets Trend (2007–2024)
This chart illustrates how NAYA Biosciences, Inc's total assets have evolved over time, based on quarterly financial data. Also see NAYA Biosciences, Inc (NAYA) market capitalisation for the company's overall valuation and market capitalisation.
NAYA Biosciences, Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NAYA Biosciences, Inc's total assets of $46.45 Million consist of 2.8% current assets and 97.2% non-current assets. Review NAYA total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.6% |
| Accounts Receivable | $174.88K | 0.4% |
| Inventory | $219.76K | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.10 Million | 39.0% |
| Goodwill | $23.54 Million | 50.7% |
Asset Composition Trend (2007–2024)
This chart illustrates how NAYA Biosciences, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest NAYA Biosciences, Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NAYA Biosciences, Inc's current assets represent 2.8% of total assets in 2024, a decrease from 6.0% in 2007.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 77.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 50.7% of total assets.
NAYA Biosciences, Inc Competitors by Total Assets
Key competitors of NAYA Biosciences, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
LENSAR Inc
NASDAQ:LNSR
|
USA | $69.56 Million |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
Australia | AU$21.12 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
NAYA Biosciences, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.16 | 0.36 |
| Quick Ratio | 0.06 | 0.12 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-16.61 Million | $-6.74 Million | $-1.23 Million |
NAYA Biosciences, Inc - Advanced Valuation Insights
This section examines the relationship between NAYA Biosciences, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.97 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 151.0% |
| Total Assets | $46.45 Million |
| Market Capitalization | $2.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values NAYA Biosciences, Inc's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NAYA Biosciences, Inc's assets grew by 151.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NAYA Biosciences, Inc (2007–2024)
The table below shows the annual total assets of NAYA Biosciences, Inc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $46.45 Million | +151.00% |
| 2023-12-31 | $18.51 Million | +398.84% |
| 2022-12-31 | $3.71 Million | -64.56% |
| 2021-12-31 | $10.47 Million | -4.39% |
| 2020-12-31 | $10.95 Million | +509.72% |
| 2019-12-31 | $1.80 Million | +130.98% |
| 2018-12-31 | $777.35K | +191.78% |
| 2017-12-31 | $266.41K | -6.92% |
| 2016-12-31 | $286.23K | -50.63% |
| 2015-12-31 | $579.79K | +220.33% |
| 2010-12-31 | $181.00K | -59.13% |
| 2009-12-31 | $442.84K | -41.85% |
| 2008-12-31 | $761.55K | +1265.48% |
| 2007-12-31 | $55.77K | -- |
About NAYA Biosciences, Inc
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as soli… Read more